Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Poxvirus vectors as HIV/AIDS vaccines in humansMixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvantsNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.An overview of cancer immunotherapy.Improving vaccine performance with adjuvants.MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.Pulmonary vaccine delivery.Role of adjuvants in modeling the immune response.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.Recent advances in vaccine adjuvants for systemic and mucosal administration.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.ISCOMs (immunostimulating complexes): the first decade.Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice.Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals
P2860
Q24531479-9056AA6B-B9FB-46F5-99B6-16BF7B6CDAABQ26995078-6826301A-31D8-421A-BE95-90571175A242Q27304735-B8F4EF3D-10A7-45AB-85BF-3844C8494243Q30431941-37577F03-8B22-4005-8CB2-FB10E829E577Q33813526-8ABF901F-6E55-4D3A-8F84-8AD674EFB921Q33940388-DEF57593-A2CF-4D63-A97B-2387DD22DB66Q33956247-762FCC7A-CD97-4738-B684-44A54A623A5EQ35546445-E41E5A2C-2528-4D18-9DCC-09B6C42906ACQ35883032-E2454694-8493-4A0B-A818-681A87DFF5BDQ35886254-D76E4C7B-6D5C-4883-9CD0-985B27C06095Q36780141-275160CC-A0DA-43C7-8C27-CAF1ED7F822CQ37803320-6D8333C1-7389-446C-8721-5FE71765563EQ37812128-3D36DAE3-EC89-4389-84B5-6D2904A6AB5CQ38356290-13E5F402-E089-4A68-8F1C-48913754633EQ38553059-A13DAEC2-E229-40FD-AF76-DF18976E6AB5Q38748193-118D6805-C48E-4A4C-A560-93EC9DDCB1AEQ41231006-494A4BAF-3547-42C0-9A9E-53595655CB65Q45790647-060BF32A-AABA-40F0-91CA-3CCF81C3DA1BQ52561260-58C5702E-AF1B-4777-B569-A135BEE97768Q57499148-5170E171-7365-476B-9F6D-5E1A84892166
P2860
Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
description
1994 nî lūn-bûn
@nan
1994 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Clinical and immunologic respo ...... HIV-infected human volunteers.
@ast
Clinical and immunologic respo ...... HIV-infected human volunteers.
@en
Clinical and immunologic responses to human immunodeficiency virus
@nl
type
label
Clinical and immunologic respo ...... HIV-infected human volunteers.
@ast
Clinical and immunologic respo ...... HIV-infected human volunteers.
@en
Clinical and immunologic responses to human immunodeficiency virus
@nl
prefLabel
Clinical and immunologic respo ...... HIV-infected human volunteers.
@ast
Clinical and immunologic respo ...... HIV-infected human volunteers.
@en
Clinical and immunologic responses to human immunodeficiency virus
@nl
P2093
P356
P1476
Clinical and immunologic respo ...... HIV-infected human volunteers.
@en
P2093
C L Dekker
D Chernoff
F Sinangil
J Baenziger
K S Steimer
R L Coleman
P304
P356
10.1093/INFDIS/170.5.1288
P407
P577
1994-11-01T00:00:00Z